Clinical Trials Browser

Completed × Advanced Non-Small Cell Lung Cancer × lorlatinib × Clear all

NCT04541706 2024-12-20

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Phase 4 Completed

100 enrolled 10 charts

Advanced Non-Small Cell Lung Cancer